Morgan Stanley analyst James Quigley downgraded MorphoSys to Underweight from Equal Weight with a price target of EUR 12.50, down from EUR 17. Quigley and the team expect a rotation from safe-haven pharma into growth/cyclical stocks in 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MOR:
- MorphoSys downgraded to Underweight from Neutral at JPMorgan
- MorphoSys price target lowered to EUR 12 from EUR 16 at Citi
- MorphoSys downgraded to Sell from Neutral at Goldman Sachs
- Hookipa Pharma promotes Schlienger to CMO, appoints Peters to board
- MorphoSys Nosedives after Alzheimer’s Drug Fails Trial
